Analysts at William Blair raised their Q1 2025 EPS estimates for Nektar Therapeutics in a research report issued to clients and investors on Thursday, March 13th. William Blair analyst A. Hsieh now ...
Investor's Business Daily on MSN9h
Incyte Loses 9% As Skin Disease Drug Looks 'Viable, But Not Competitive'Incyte's skin disease treatment looks "viable, but not competitive with biologics," an analyst said Monday as Incyte stock fell.
Butterfly Network exceeded Q4 estimates with 35% revenue growth. William Blair sees strong upside, citing homecare potential ...
We recently published a list of 11 Best Reddit Stocks to Invest In. In this article, we are going to take a look at where ...
Software company DocuSign (DOCU) scored a rating upgrade from Hold to Buy from William Blair, thanks to the optimism about ...
A Wall Street analyst believes Palantir's (NASDAQ: PLTR) expanding artificial intelligence (AI) ecosystem, marked by major ...
William Blair analyst Louie DiPalma maintained a Hold rating on Science Applications (SAIC – Research Report) today. The company’s shares ...
Equities research analysts at William Blair issued their Q1 2026 earnings estimates for shares of Sprinklr in a note issued ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback